Reasons why it is worth to use a combined oral contraceptive pill containing desogestrel Review article
Article Sidebar
Published:
Sep 30, 2016
Keywords:
oral contraceptive pill, desogestrel, ethinylestradiol
Main Article Content
Abstract
Oral contraceptive pill containing desogestrel and ethinylestradiol has been a commonly used form of contraception for many years now. A large amount of data collected in clinical trials confirms superb contraceptive efficacy, very good tolerability and cycle control with the use of this method.
Article Details
How to Cite
Nowakowski, A. (2016). Reasons why it is worth to use a combined oral contraceptive pill containing desogestrel. Medycyna Faktow (J EBM), 9(3(32), 242-243. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2229
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Berek J.S., Novak E.: Ginekologia. Tom 1. Wydawnictwo MediPage, Warszawa 2008.
2. Fotherby K.: Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995; 51(1): 3-12.
3. Marianowski L., Grzechocińska B.: [Clinical effectiveness of Marvelon]. Ginekol. Pol. 1995; 66(5): 294-296.
4. Ferguson H., Vree M.L., Wilpshaar J., Eskes T.K.: Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive. Eur. J. Contracept. Reprod. Health Care 2000; 5(1): 35-45.
5. Winkler U.H., Ferguson H., Mulders J.A.: Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69(6): 469-476.
6. Anttila L., Neunteufel W., Petraglia F. et al.: Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis. Clin. Drug. Investig. 2011; 31(8): 519-525.
2. Fotherby K.: Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995; 51(1): 3-12.
3. Marianowski L., Grzechocińska B.: [Clinical effectiveness of Marvelon]. Ginekol. Pol. 1995; 66(5): 294-296.
4. Ferguson H., Vree M.L., Wilpshaar J., Eskes T.K.: Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive. Eur. J. Contracept. Reprod. Health Care 2000; 5(1): 35-45.
5. Winkler U.H., Ferguson H., Mulders J.A.: Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception 2004; 69(6): 469-476.
6. Anttila L., Neunteufel W., Petraglia F. et al.: Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis. Clin. Drug. Investig. 2011; 31(8): 519-525.